Neuroprotective Agents With Reperfusion Therapies in Ischemic Stroke: Evidence From Recent Randomized Trials. [PDF]
CureusWesley MJ +10 more
europepmc +3 more sources
Therapeutic potential of agmatine in the experimental autoimmune encephalomyelitis [PDF]
Vojnosanitetski Pregled, 2021 Background/Aim. Experimental autoimmune encephalomyelitis (EAE) is a model of multiple sclerosis (MS), in which we investigated the neuroprotective effect of agmatine (AGM), known as a primary amine produced via the decarboxylation of L-arginine. Methods.
Stevanović Ivana +4 more
doaj +1 more source
Exploration of Neuroprotective Therapy, 2023 Acute ischemic stroke (AIS) is the leading cause of disability and one of the top causes of mortality worldwide. The current standard of care is reperfusion therapy including intravenous thrombolysis (IVT) and thrombectomy. However, these treatments have
Grace YY Chia +5 more
doaj +1 more source
Graph theoretical network analysis, in silico exploration, and validation of bioactive compounds from Cynodon dactylon as potential neuroprotective agents against α-synuclein [PDF]
BioImpacts, 2022 Introduction: Parkinson's disease (PD) is a chronic, devastating neurodegenerative disorder marked by the death of dopaminergic neurons in the midbrain's substantia nigra pars compacta (Snpc). In alpha-synuclein (α-Syn) self-aggregation, the existence of
Raja Rajeswari Rajeshkumar +9 more
doaj +1 more source
The Antioxidative Effects of Picein and Its Neuroprotective Potential: A Review of the Literature
Molecules, 2022 Neurodegenerative diseases (NDDs) are the main cause of dementia in the elderly, having no cure to date, as the currently available therapies focus on symptom remission.
Leila Elyasi +3 more
doaj +1 more source
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +9 more sources
Frontiers in Pharmacology, 2022 Background: Renin-angiotensin system (RAS) inhibitors have been suggested as protective agents in Parkinson’s disease (PD). However, epidemiological evidence on the association between RAS inhibitors and the development of PD is inconsistent.Objectives ...
Youngkwon Jo +6 more
doaj +1 more source
Molecules, 2023 Neurodegeneration is a slow and progressive loss of neuronal cells or their function in specific regions of the brain or in the peripheral system.
Daniele Zampieri +8 more
doaj +1 more source
Neuroprotective Agents in the Intensive Care Unit - Neuroprotective Agents in ICU -
Journal of Pharmacopuncture, 2018 Neuroprotection or prevention of neuronal loss is a complicated molecular process that is mediated by various cellular pathways. Use of different pharmacological agents as neuroprotectants has been reported especially in the last decades.
Yunes Panahi +5 more
doaj +1 more source
Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]
, 2019 The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto +5 more
core +1 more source